• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

Comprehensive Guide to rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid (CAS No. 2227678-64-8)

The compound rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid (CAS No. 2227678-64-8) is a chiral cyclopropane derivative that has garnered significant attention in pharmaceutical research and organic synthesis. With its unique structural features combining a cyclopropane carboxylic acid moiety and a 1,5-dimethylpyrazole group, this compound serves as a valuable building block in medicinal chemistry and drug discovery.

Recent trends in drug development have shown increasing interest in cyclopropane-containing compounds due to their ability to modulate biological activity and improve metabolic stability. The rac-(1R,2R) configuration of this particular compound makes it especially interesting for studying stereospecific interactions in biological systems. Researchers frequently search for information about "chiral cyclopropane synthesis" and "pyrazole derivatives in drug design", areas where this compound demonstrates significant potential.

The molecular structure of rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid features several pharmacologically relevant characteristics. The cyclopropane ring introduces significant ring strain, which can enhance binding affinity to biological targets. Meanwhile, the carboxylic acid functionality provides a handle for further derivatization or salt formation, addressing common queries about "modifying cyclopropane carboxylic acids" in drug development.

In synthetic applications, this compound serves as a versatile intermediate for creating more complex molecules. The presence of both the pyrazole heterocycle and cyclopropane moiety in one molecule makes it particularly valuable for medicinal chemists investigating "heterocyclic compound libraries" and "constrained analogs in lead optimization". Its CAS number 2227678-64-8 has become increasingly important for precise identification in chemical databases and patent literature.

The pharmaceutical industry has shown growing interest in rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid as a potential scaffold for kinase inhibitors and GPCR modulators. Current research trends focusing on "three-dimensional fragment-based drug discovery" and "sp3-rich compounds" highlight the relevance of such structurally constrained molecules. The compound's chiral centers offer opportunities for exploring stereospecific biological effects, addressing frequent searches about "importance of chirality in drug design".

From a synthetic chemistry perspective, the preparation of rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid involves challenging transformations that interest researchers investigating "stereoselective cyclopropanation methods". The compound's stability profile and solubility characteristics make it suitable for various experimental conditions, answering common questions about "handling cyclopropane derivatives" in laboratory settings.

Analytical characterization of this compound typically employs advanced techniques such as chiral HPLC and X-ray crystallography, reflecting the pharmaceutical industry's focus on "characterization of stereoisomers". The 1,5-dimethylpyrazole component contributes to the molecule's overall properties, influencing its hydrogen bonding capacity and lipophilicity - key parameters frequently searched in relation to "molecular property optimization".

In drug metabolism studies, the rac-(1R,2R) configuration presents interesting case studies for researchers examining "stereoselective metabolism" patterns. The compound's carboxylic acid group allows for the formation of various prodrugs, addressing practical concerns about "improving oral bioavailability" of drug candidates. These aspects contribute to its growing importance in preclinical research.

The commercial availability of rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid (CAS 2227678-64-8) has expanded in recent years, responding to increased demand from pharmaceutical and biotechnology companies. Suppliers often highlight its purity specifications and stereochemical integrity, answering industry queries about "quality control of chiral building blocks". The compound's stability under various storage conditions makes it practical for research applications.

Future research directions for this compound likely include exploration of its individual enantiomers, as the pharmaceutical industry increasingly focuses on "single enantiomer drugs". The rac-(1R,2R) form serves as an important reference point for such studies, while its structural features continue to inspire new synthetic methodologies in organic chemistry.

Environmental and safety considerations for rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid follow standard laboratory chemical handling protocols. Researchers often search for information about "safe handling of carboxylic acid compounds" and "disposal of heterocyclic chemicals", areas where this compound presents no exceptional concerns when proper procedures are followed.

In summary, rac-(1R,2R)-2-(1,5-dimethyl-1H-pyrazol-4-yl)cyclopropane-1-carboxylic acid (CAS No. 2227678-64-8) represents an important structural class in modern medicinal chemistry. Its combination of cyclopropane strain, chirality, and heterocyclic functionality addresses multiple current research trends, from fragment-based drug discovery to stereoselective synthesis. As pharmaceutical research continues to explore three-dimensional chemical space, compounds like this will remain valuable tools for drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)